studies

388A AASLD ABSTRACTS HEPATOLOGY, October, 2015
Disclosures:
Adriaan J. van der Meer - Consulting: Gilead; Speaking and Teaching: MSD,
Gilead
Harry L. Janssen - Consulting: AbbVie, Bristol Myers Squibb, GSK, Gilead Sciences,
Innogenetics, Merck, Medtronic, Novartis, Roche, Janssen, Medimmune,
ISIS Pharmaceuticals, Tekmira; Grant/Research Support: AbbVie, Bristol Myers
Squibb, Gilead Sciences, Innogenetics, Merck, Medtronic, Novartis, Roche,
Janssen, Medimmune
Jordan J. Feld - Advisory Committees or Review Panels: Merck, Janssen, Gilead,
AbbVie, Theravance, Bristol Meiers Squibb; Grant/Research Support: AbbVie,
Boehringer Ingelheim, Janssen, Gilead, Merck
The following authors have nothing to disclose: Hooman Farhang Zangneh, William
W. Wong, Beate Sander, Chaim M. Bell, Khalid Mumtaz, Matt Kowgier,
Sean P. Cleary, Kelvin K. Chan
351
Whole blood coagulation tests are not equally able to
detect haemostatic prothrombotic alterations in patients
with liver cirrhosis and hepatocellular carcinoma (HCC):
rotational thromboelastometry versus thrombingeneration
test.
Alberto Zanetto 1 , Alberto Ferrarese 1 , Alessandro Vitale 2 , Umberto
Cillo 2 , Mariangela Fadin 3 , Sabrina Gavasso 3 , Claudia M. Radu 3 ,
Luca Spiezia 3 , Fabio Farinati 1 , Patrizia Burra 1 , Paolo Simioni 3 ,
Marco Senzolo 1 ; 1 Surgery, Oncology and Gastroenterology,
University of Padua, Gastroenterology, Padova, Italy; 2 Surgery,
Oncology and Gastroenterology, University of Padua, Liver Transplantation
Unit, Padova, Italy; 3 Department of Medicine, Padua
University Hospital, V Chair of Internal Medicine, Padova, Italy
Background and aim: neoplasms are considered as one of the
main important cause of acquired thrombophilia but studies
exploring coagulation imbalance induced by HCC in liver cirrhosis
are lacking. The aim of this study study was to evaluate the
thrombophilic role of HCC in patients with cirrhosis. Methods:
cirrhotic patients with and without HCC were enrolled in the
study and underwent rotational thromboelastometry (ROTEM),
platelet count, determination of levels of pro and anticoagulation
factors and thrombin generation test (TG), with and without
trombomodulin (TM). Results: 76 cirrhotics, of whom 41 with
HCC, were included. Volume of active HCC was >5 cm 3 in
18 patients. Levels of pro and anticoagulation factors were
similar in patients with and without HCC, but fibrinogen was
increased in HCC patients with tumor volume >5cm 3 compared
to those with 5cm 3 compared to those with